Why Verastem, Inc.’s (VSTM) Stock Is Up 6.96%
As of Friday, August 21, Verastem, Inc.’s VSTM share price has surged by 6.96%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Commentary & Analysis
Why Verastem, Inc.’s (VSTM) Stock Is Up 5.71%
As of Tuesday, August 18, Verastem, Inc.’s VSTM share price has surged by 5.71%, which has investors questioning if this is right time to sell.Michael Rose
Why Verastem, Inc.’s (VSTM) Stock Is Up 5.02%
As of Monday, August 17, Verastem, Inc.’s VSTM share price has surged by 5.02%, which has investors questioning if this is right time to sell.Michael Rose
Why Verastem, Inc.’s (VSTM) Stock Is Up 8.21%
As of Friday, August 07, Verastem, Inc.’s VSTM share price has surged by 8.21%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Verastem, Inc.’s (VSTM) Stock Is Down 7.21%
As of Friday, July 31, Verastem, Inc.’s VSTM share price has dipped by 7.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | VSTM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $742.6 | $282.4 | 41% |
|
| Shares Out (Mil) | 100.1 | 54.0 | 62% |
|
| Institutional Ownership | 99.3% | 93.1% | 86% |
|
| Float (Mil) | 70.6 | 42.2 | 55% |
|
| Beta | 0.29 | 0.94 | 17% |
|
| Avg Daily Volume (000s) | 2,002 | 482 | 83% |
|
| Price Change (52-week) |
(22.4%) | 59.9% | 29% |
|
| Growth | VSTM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (19.0%) | 14.1% | 2% |
|
| Net Income (5yr) | (25.3%) | (10.1%) | 16% |
|
| EPS (5yr) | 10.6% | 15.9% | 48 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 31.3% | (15.6%) | 87% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 1 | |
| Current EPS | ($0.430) | ($1.800) | ($0.750) | |
| Month Ago EPS | ($0.373) | ($1.557) | ($1.160) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.373) | ($1.557) | ($1.160) | |
| Year/Year Chg | 22.9% | (40.4%) | (86.1%) | |
| Financials | VSTM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $88 | $37 | 25% |
|
| Net Income (TTM) (Mil) | ($203) | ($43) | 7% |
|
| EPS (TTM) | ($2.282) | ($1.500) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($162) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($28) | $2 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $78 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $572 | $190 | 35% |
|
| Valuation | VSTM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.91 | 2.84 | 94% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VSTM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 87.6% | 66.9% | 93% |
|
| Net Margin | (231.6%) | (74.2%) | 4% |
|
| ROA | (100.7%) | (47.7%) | 5% |
|
| ROE | (471.2%) | (55.0%) | 1% |
|
| Liabilities to Assets | 75.8% | 29.8% | 71% |
|
| F-Score | 3 | 3 | 18% |
|
Verastem, Inc. did not pass any screens on 9/4/2026.
